2024-519150-37-00已完成2 期
An phase I study of BI 765063 (a monoclonal antibody) as single agent and in combination with BI 754091 (a PD-1) to characterize safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in patients with advanced solid tumour
OSE Immunotherapeutics, OSE Immunotherapeutics1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2024年12月11日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 78
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Lucie Begert
Scientific
OSE Immunotherapeutics
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to test different doses of BI 765063 alone and in combination with BI 754091 in Japanese patients with different types of advanced cancer (solid tumors)JPRN-jRCT2031200355akajima Michiko36
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisRheumatoid arthritisEUCTR2012-002945-40-ESBoehringer Ingelheim International GmbH600
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisMedDRA version: 17.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2012-002945-40-HUBoehringer Ingelheim International GmbH650
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisMedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2012-002945-40-BGBoehringer Ingelheim International GmbH650
进行中（未招募）
1 期
BI695501 compared to adalimumab in patients with active rheumatoid arthritisRheumatoid arthritisEUCTR2012-002945-40-EEBoehringer Ingelheim International GmbH650